{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:51:12Z","timestamp":1785279072476,"version":"3.55.0"},"reference-count":37,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI 15614"],"award-info":[{"award-number":["AI 15614"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010279","name":"Interleukin Foundation for Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010279","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.00131","type":"journal-article","created":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T22:33:16Z","timestamp":1486593196000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":67,"title":["Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure"],"prefix":"10.3389","volume":"8","author":[{"given":"Giulio","family":"Cavalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Foppoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cabrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Dinarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moreno","family":"Tresoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3389\/fimmu.2013.00391","article-title":"The interleukin-1alpha precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines","volume":"4","author":"Kim","year":"2013","journal-title":"Front Immunol"},{"issue":"3","key":"B2","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/j.ijcard.2013.12.137","article-title":"Formation of the inflammasome in acute myocarditis","volume":"171","author":"Toldo","year":"2014","journal-title":"Int J Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fimmu.2015.00054","article-title":"ATP-induced IL-1beta specific secretion: true under stringent conditions","volume":"6","author":"Stoffels","year":"2015","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fimmu.2014.00553","article-title":"IL-1 receptor-associated kinase signaling and its role in inflammation, cancer progression, and therapy resistance","volume":"5","author":"Jain","year":"2014","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3389\/fimmu.2013.00396","article-title":"Ligands and receptors of the interleukin-1 family in immunity and disease","volume":"4","author":"Garlanda","year":"2013","journal-title":"Front Immunol"},{"issue":"12","key":"B6","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1093\/rheumatology\/kew325","article-title":"Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation","volume":"55","author":"Cavalli","year":"2016","journal-title":"Rheumatology"},{"issue":"2","key":"B7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1113\/expphysiol.2012.069021","article-title":"The heart on fire: inflammasome and cardiomyopathy","volume":"98","author":"Abbate","year":"2013","journal-title":"Exp Physiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fimmu.2014.00281","article-title":"Oncogene-induced senescence as a new mechanism of disease: the paradigm of erdheim-chester disease","volume":"5","author":"Cavalli","year":"2014","journal-title":"Front Immunol"},{"issue":"10","key":"B9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/annrheumdis-2012-202542","article-title":"The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases","volume":"72","author":"Cavalli","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"B10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ejim.2015.03.004","article-title":"Erdheim-Chester disease","volume":"26","author":"Campochiaro","year":"2015","journal-title":"Eur J Intern Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fimmu.2013.00181","article-title":"Opposing functions of classic and novel IL-1 family members in gut health and disease","volume":"4","author":"Lopetuso","year":"2013","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fimmu.2013.00167","article-title":"New insights in the immunobiology of IL-1 family members","volume":"4","author":"van de Veerdonk","year":"2013","journal-title":"Front Immunol"},{"issue":"12","key":"B13","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1093\/rheumatology\/kev269","article-title":"Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies","volume":"54","author":"Cavalli","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"B14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jbspin.2010.09.014","article-title":"Adult-onset Still\u2019s disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra","volume":"78","author":"Raffeiner","year":"2011","journal-title":"Joint Bone Spine"},{"issue":"4","key":"B15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/03009742.2014.992949","article-title":"Efficacy and safety of biological agents in adult-onset Still\u2019s disease","volume":"44","author":"Cavalli","year":"2015","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"B16","first-page":"623","article-title":"Anakinra for myocarditis in juvenile idiopathic arthritis","volume":"40","author":"Movva","year":"2013","journal-title":"Tex Heart Inst J"},{"issue":"1","key":"B17","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/j.ijcard.2013.12.151","article-title":"Cardiac magnetic resonance in myocarditis from adult onset Still\u2019s disease successfully treated with anakinra","volume":"172","author":"Choi","year":"2014","journal-title":"Int J Cardiol"},{"issue":"14","key":"B18","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"issue":"5","key":"B19","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1097\/CCM.0000000000000920","article-title":"Extracorporeal membrane oxygenation for the support of adults with acute myocarditis","volume":"43","author":"Diddle","year":"2015","journal-title":"Crit Care Med"},{"issue":"2","key":"B20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/CCM.0b013e3181bc8293","article-title":"Extracorporeal membrane oxygenation for the support of infants, children, and young adults with acute myocarditis: a review of the Extracorporeal Life Support Organization registry","volume":"38","author":"Rajagopal","year":"2010","journal-title":"Crit Care Med"},{"issue":"8","key":"B21","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1097\/CCM.0000000000001654","article-title":"Treating life-threatening myocarditis by blocking interleukin-1","volume":"44","author":"Cavalli","year":"2016","journal-title":"Crit Care Med"},{"issue":"1","key":"B22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/10428190701713630","article-title":"Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome","volume":"49","author":"Tong","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"B23","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1164\/rccm.201412-2150LE","article-title":"Treating pulmonary silicosis by blocking interleukin 1","volume":"191","author":"Cavalli","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"B24","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.amjcard.2009.12.059","article-title":"Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study)","volume":"105","author":"Abbate","year":"2010","journal-title":"Am J Cardiol"},{"issue":"10","key":"B25","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.amjcard.2013.01.287","article-title":"Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]","volume":"111","author":"Abbate","year":"2013","journal-title":"Am J Cardiol"},{"issue":"6","key":"B26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study","volume":"36","author":"Morton","year":"2015","journal-title":"Eur Heart J"},{"issue":"7","key":"B27","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1097\/00003246-199907000-00018","article-title":"Tumor necrosis factor-a and interleukin-1b synergistically depress human myocardial function","volume":"27","author":"Cain","year":"1999","journal-title":"Crit Care Med"},{"issue":"3","key":"B28","doi-asserted-by":"publisher","first-page":"e33438","DOI":"10.1371\/journal.pone.0033438","article-title":"Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure","volume":"7","author":"Van Tassell","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"B29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART Pilot Study)","volume":"113","author":"Van Tassell","year":"2014","journal-title":"Am J Cardiol"},{"issue":"20","key":"B30","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","article-title":"Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis","volume":"117","author":"Ikonomidis","year":"2008","journal-title":"Circulation"},{"issue":"5","key":"B31","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/CCM.0b013e31820ead45","article-title":"Outcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support","volume":"39","author":"Mirabel","year":"2011","journal-title":"Crit Care Med"},{"issue":"10","key":"B32","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1056\/NEJM200003093421003","article-title":"Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis","volume":"342","author":"McCarthy","year":"2000","journal-title":"N Engl J Med"},{"issue":"4","key":"B33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/BOR.0000000000000303","article-title":"Viral myocarditis","volume":"28","author":"Rose","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1097\/00003246-199707000-00010","article-title":"Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial","volume":"25","author":"Opal","year":"1997","journal-title":"Crit Care Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/00003246-199401000-00008","article-title":"Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial","volume":"22","author":"Fisher","year":"1994","journal-title":"Crit Care Med"},{"issue":"23","key":"B36","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1001\/jama.271.23.1836","article-title":"Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group","volume":"271","author":"Fisher","year":"1994","journal-title":"JAMA"},{"issue":"2","key":"B37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00131\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T22:33:20Z","timestamp":1486593200000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00131\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,9]]},"references-count":37,"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.00131","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,9]]}}}